A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies Journal Article
| Authors: | Chan, A.; Cameron, M. C.; Garden, B.; Boers-Doets, C. B.; Schindler, K.; Epstein, J. B.; Choi, J.; Beamer, L.; Roeland, E.; Russi, E. G.; Bensadoun, R. J.; Teo, Y. L.; Chan, R. J.; Shih, V.; Bryce, J.; Raber-Durlacher, J.; Gerber, P. A.; Freytes, C. O.; Rapoport, B.; LeBoeuf, N.; Sibaud, V.; Lacouture, M. E. |
| Article Title: | A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies |
| Abstract: | Purpose: Dermatologic adverse events (dAEs) in cancer treatment are frequent with the use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL. Methods: A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments. Results: Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index (DLQI), and DIELH-24) and two were symptom-specific (functional assessment of cancer therapy-epidermal growth factor receptor inhibitor-18 (FACT-EGFRI-18) and hand-foot syndrome 14 (HFS-14)). Conclusions: While there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies. © 2015, Springer-Verlag Berlin Heidelberg. |
| Keywords: | functional assessment; skin toxicity; outcome assessment; antineoplastic agent; quality of life; cetuximab; panitumumab; protein tyrosine kinase inhibitor; systematic review; clinical evaluation; skin disease; health-related quality of life; patient-reported outcomes; hand foot syndrome; drug induced disease; epidermal growth factor receptor kinase inhibitor; targeted cancer therapy; clinical assessment tool; molecularly targeted therapy; patient reported outcome; skindex 16; dermatologic adverse events; dermatology life quality index; human; priority journal; article; dielh 24; skin disease assessment; skindex 29 |
| Journal Title: | Supportive Care in Cancer |
| Volume: | 23 |
| Issue: | 8 |
| ISSN: | 0941-4355 |
| Publisher: | Springer Verlag |
| Date Published: | 2015-08-01 |
| Start Page: | 2231 |
| End Page: | 2244 |
| Language: | English |
| DOI: | 10.1007/s00520-014-2564-x |
| PROVIDER: | scopus |
| PUBMED: | 25564221 |
| PMCID: | PMC4996115 |
| DOI/URL: | |
| Notes: | Export Date: 3 August 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work